Endocrine Society experts estimate that between 5 and 14 percent of people with hypertension also have undiagnosed primary ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

Delayed diagnosis of hypertension after initial elevated BP measurement was tied to lower rates of antihypertensive drug ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

The BaxHTN study met its primary endpoint, and researchers will present more data at the ESC Congress later this summer.

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year ...

Endocrine Society experts encouraged more widespread screening for a common hormonal cause of high blood pressure known as ...

Fewer than 10 percent of people with hypertension had their blood sugar under control & fewer than 66 percent of diabetics ...

A new study published in the journal of Hypertension showed that the white matter hyperintensity volume was higher 15 years ...

Discover why customizable blood pressure alerts in EMRs, combined with team-based workflows, may be key to catching more ...